Catechol O-methyltransferase pharmacogenomics and selective serotonin reuptake inhibitor response

Y. Ji, Joanna M Biernacka, K. Snyder, M. Drews, L. L. Pelleymounter, C. Colby, Liewei M Wang, D. A. Mrazek, Richard M Weinshilboum

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

We applied a systematic pharmacogenetic approach to investigate the role of genetic variation in the gene encoding catechol O-methyltransferase (COMT) in individual variation in selective serotonin reuptake inhibitor (SSRI) response among depressed patients. In all, 23 single-nucleotide polymorphisms (SNPs) in COMT were genotyped using DNA from the Sequenced Treatment Alternatives to Relieve Depression (STAR D) study (N1914). One SNP, rs13306278, located in the distal promoter region of COMT, showed significant association with remission in White non-Hispanic (WNH) subjects (P0.038). Electromobility shift assay for rs13306278 showed alternation in the ability of the variant sequence to bind nuclear proteins. A replication study was performed using samples from the Mayo Clinic Pharmacogenetics Research Network Citalopram/Escitalopram Pharmacogenomic study (N422) that demonstrated a similar trend for association. Our findings suggest that novel genetic markers in the COMT distal promoter may influence SSRI response phenotypes.

Original languageEnglish (US)
Pages (from-to)78-85
Number of pages8
JournalPharmacogenomics Journal
Volume12
Issue number1
DOIs
StatePublished - 2012

Fingerprint

Catechol O-Methyltransferase
Pharmacogenetics
Serotonin Uptake Inhibitors
Citalopram
Single Nucleotide Polymorphism
Nuclear Proteins
Genetic Markers
Genetic Promoter Regions
Phenotype
DNA
Research
Genes
Therapeutics

Keywords

  • catechol O-methyltransferase
  • COMT
  • major depressive disorder
  • pharmacogenetics
  • selective serotonin reuptake inhibitor
  • STAR*D

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Pharmacology

Cite this

Catechol O-methyltransferase pharmacogenomics and selective serotonin reuptake inhibitor response. / Ji, Y.; Biernacka, Joanna M; Snyder, K.; Drews, M.; Pelleymounter, L. L.; Colby, C.; Wang, Liewei M; Mrazek, D. A.; Weinshilboum, Richard M.

In: Pharmacogenomics Journal, Vol. 12, No. 1, 2012, p. 78-85.

Research output: Contribution to journalArticle

Ji, Y. ; Biernacka, Joanna M ; Snyder, K. ; Drews, M. ; Pelleymounter, L. L. ; Colby, C. ; Wang, Liewei M ; Mrazek, D. A. ; Weinshilboum, Richard M. / Catechol O-methyltransferase pharmacogenomics and selective serotonin reuptake inhibitor response. In: Pharmacogenomics Journal. 2012 ; Vol. 12, No. 1. pp. 78-85.
@article{a20eabfb98854309883370bbe64ed3df,
title = "Catechol O-methyltransferase pharmacogenomics and selective serotonin reuptake inhibitor response",
abstract = "We applied a systematic pharmacogenetic approach to investigate the role of genetic variation in the gene encoding catechol O-methyltransferase (COMT) in individual variation in selective serotonin reuptake inhibitor (SSRI) response among depressed patients. In all, 23 single-nucleotide polymorphisms (SNPs) in COMT were genotyped using DNA from the Sequenced Treatment Alternatives to Relieve Depression (STAR D) study (N1914). One SNP, rs13306278, located in the distal promoter region of COMT, showed significant association with remission in White non-Hispanic (WNH) subjects (P0.038). Electromobility shift assay for rs13306278 showed alternation in the ability of the variant sequence to bind nuclear proteins. A replication study was performed using samples from the Mayo Clinic Pharmacogenetics Research Network Citalopram/Escitalopram Pharmacogenomic study (N422) that demonstrated a similar trend for association. Our findings suggest that novel genetic markers in the COMT distal promoter may influence SSRI response phenotypes.",
keywords = "catechol O-methyltransferase, COMT, major depressive disorder, pharmacogenetics, selective serotonin reuptake inhibitor, STAR*D",
author = "Y. Ji and Biernacka, {Joanna M} and K. Snyder and M. Drews and Pelleymounter, {L. L.} and C. Colby and Wang, {Liewei M} and Mrazek, {D. A.} and Weinshilboum, {Richard M}",
year = "2012",
doi = "10.1038/tpj.2010.69",
language = "English (US)",
volume = "12",
pages = "78--85",
journal = "Pharmacogenomics Journal",
issn = "1470-269X",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Catechol O-methyltransferase pharmacogenomics and selective serotonin reuptake inhibitor response

AU - Ji, Y.

AU - Biernacka, Joanna M

AU - Snyder, K.

AU - Drews, M.

AU - Pelleymounter, L. L.

AU - Colby, C.

AU - Wang, Liewei M

AU - Mrazek, D. A.

AU - Weinshilboum, Richard M

PY - 2012

Y1 - 2012

N2 - We applied a systematic pharmacogenetic approach to investigate the role of genetic variation in the gene encoding catechol O-methyltransferase (COMT) in individual variation in selective serotonin reuptake inhibitor (SSRI) response among depressed patients. In all, 23 single-nucleotide polymorphisms (SNPs) in COMT were genotyped using DNA from the Sequenced Treatment Alternatives to Relieve Depression (STAR D) study (N1914). One SNP, rs13306278, located in the distal promoter region of COMT, showed significant association with remission in White non-Hispanic (WNH) subjects (P0.038). Electromobility shift assay for rs13306278 showed alternation in the ability of the variant sequence to bind nuclear proteins. A replication study was performed using samples from the Mayo Clinic Pharmacogenetics Research Network Citalopram/Escitalopram Pharmacogenomic study (N422) that demonstrated a similar trend for association. Our findings suggest that novel genetic markers in the COMT distal promoter may influence SSRI response phenotypes.

AB - We applied a systematic pharmacogenetic approach to investigate the role of genetic variation in the gene encoding catechol O-methyltransferase (COMT) in individual variation in selective serotonin reuptake inhibitor (SSRI) response among depressed patients. In all, 23 single-nucleotide polymorphisms (SNPs) in COMT were genotyped using DNA from the Sequenced Treatment Alternatives to Relieve Depression (STAR D) study (N1914). One SNP, rs13306278, located in the distal promoter region of COMT, showed significant association with remission in White non-Hispanic (WNH) subjects (P0.038). Electromobility shift assay for rs13306278 showed alternation in the ability of the variant sequence to bind nuclear proteins. A replication study was performed using samples from the Mayo Clinic Pharmacogenetics Research Network Citalopram/Escitalopram Pharmacogenomic study (N422) that demonstrated a similar trend for association. Our findings suggest that novel genetic markers in the COMT distal promoter may influence SSRI response phenotypes.

KW - catechol O-methyltransferase

KW - COMT

KW - major depressive disorder

KW - pharmacogenetics

KW - selective serotonin reuptake inhibitor

KW - STARD

UR - http://www.scopus.com/inward/record.url?scp=85027918227&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027918227&partnerID=8YFLogxK

U2 - 10.1038/tpj.2010.69

DO - 10.1038/tpj.2010.69

M3 - Article

VL - 12

SP - 78

EP - 85

JO - Pharmacogenomics Journal

JF - Pharmacogenomics Journal

SN - 1470-269X

IS - 1

ER -